Growth Metrics

10x Genomics (TXG) Debt to Equity (2018 - 2019)

10x Genomics recorded quarterly Debt to Equity of $0.07 in Q4 2019, little changed quarter-over-quarter from $0.07 in Q3 2019, and up 152.44% year-over-year from $0.03 in Q4 2018.

10x Genomics' Debt to Equity history runs 2 years deep, the most recent figure standing at $0.07 for Q4 2019.

  • In Q4 2019, Debt to Equity rose 152.44% year-over-year to $0.07; the TTM figure through Dec 2019 stood at $0.07 (up 152.44% YoY), while the FY2019 annual figure was $0.07, up 152.44% from the prior year.
  • Debt to Equity came in at $0.07 for Q4 2019 at 10x Genomics, roughly flat from $0.07 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.07 in Q4 2019 to a low of -$0.13 in Q4 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Veeva Systems 30.85 Bn 24.28 Bn 622.47 Mn -
2 BrightSpring Health Services 12.29 Bn 11.41 Bn 482.22 Mn 1.26
3 Healthequity 7.80 Bn 7.48 Bn 256.31 Mn 0.46
4 Hinge Health 4.82 Bn 4.51 Bn 154.23 Mn -
5 Doximity 4.21 Bn 3.46 Bn 125.97 Mn -
6 Waystar Holding 4.18 Bn 4.03 Bn 268.04 Mn 0.37
7 10x Genomics 3.78 Bn 3.24 Bn 106.18 Mn -
8 Privia Health 2.65 Bn 2.28 Bn 595.71 Mn -
9 Omnicell 1.95 Bn 1.78 Bn 140.36 Mn -
10 Teladoc Health 1.42 Bn 672.39 Mn 562.57 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 0.07
Sep 30, 2019 0.07
Dec 31, 2018 -0.13